.png)
Illustration of the NIR-PICT³ treatment in action: (1) Antibodies (mAb) carrying a light-activated dye (IR700) and tiny iron particles (green) attach to cancer cells in a tumor. The dye’s glow and the iron particles let researchers track the drug using fluorescence imaging and MRI. When near-infrared (NIR) light shines on the tumor, (2) the targeted cells burst, (3) the particles heat up, and (4) they trigger damaging chemical reactions. (5) The light also opens up the tumor’s blood vessels, letting more particles in. (6) The heat then destroys nearby cancer cells that the drug could not target.
Image Credit: Adapted from Matsuoka et al., Journal of Nanobiotechnology (2026)
(CC BY-NC-ND 4.0)
Scientific Frontline: Extended "At a Glance" Summary: Iron Oxide Nanoparticle-Enhanced Near-Infrared Photoimmunotherapy (NIR-PICT3)
The Core Concept: Researchers at Nagoya University developed an enhanced light-based cancer therapy, termed near-infrared photoimmuno-chemodynamic thermal targeting therapy (NIR-PICT3), by attaching 20 nm iron oxide nanoparticles to dye-carrying, cancer-targeting antibodies. In mouse models, this platform enables magnetic resonance imaging (MRI) tumor tracking and destroys both targeted cancer cells and neighboring untargeted tumor cells that typically evade standard treatment.
Key Distinction/Mechanism: Unlike conventional near-infrared photoimmunotherapy (NIR-PIT), which only ruptures cells expressing the target protein epidermal growth factor receptor (EGFR) and suffers from limited surface-level dye visibility, NIR-PICT3 accumulates in tumors after bloodstream injection to provide clear MRI contrast while executing a triple-action assault under near-infrared (NIR) light. Irradiation causes targeted cells to burst, heats the iron oxide particles to kill adjacent antigen-negative cells via a newly identified "photothermal bystander effect," and triggers damaging chemical reactions inside cancer cells. Furthermore, the initial light exposure dilates tumor blood vessels, allowing subsequent nanoparticle accumulation and amplifying thermal destruction with each repeated round of therapy.
Origin/History: Conventional NIR-PIT received conditional approval in Japan in 2020 for treating recurrent head and neck cancer and has since advanced to late-stage clinical trials in the United States. Prior attempts to combine antibodies with nanoparticles failed to achieve effective tumor accumulation because larger constructs were sequestered by the liver or spleen, though larger iron oxide particles have already gained clinical approval as MRI contrast agents.
Major Frameworks/Components:
- NIR-PICT3 Nanotheranostic Platform: A composite agent pairing a tumor-seeking monoclonal antibody (mAb) with the light-activated dye IR700 and 20 nm iron oxide nanoparticles. Its compact 20 nm diameter prevents premature clearance by the liver and spleen, enabling strong intratumoral accumulation and bimodal fluorescence and MRI tracking.
- Photothermal Bystander Effect: A newly defined mechanism in which NIR-irradiated iron oxide nanoparticles generate localized heat that spreads to adjacent cancer cells lacking the target protein. This thermal diffusion eliminates heterogeneous tumor populations that survive conventional antigen-specific light therapy.
- Triple-Mode Cell Destruction: Under NIR illumination, the platform simultaneously induces cell-membrane bursting via photoimmunotherapy, localized hyperthermia via photothermal heating, and intracellular chemical damage observed in human cancer cell tests.
- Vascular Permeability Amplification: The first round of NIR light opens tumor blood vessels, increasing subsequent nanoparticle influx into the tumor microenvironment. Each repeated illumination cycle consequently generates greater heat, yielding complete remission in four of ten homogeneous-tumor mice and three of six mixed-tumor mice without significant weight loss or liver toxicity.
Branches of Science: Nanomedicine, Photoimmunotherapy, Molecular Oncology, Diagnostic Medical Imaging, and Nanomaterials Engineering.
Future Application: Because laboratory tests on human cancer cells demonstrated that the antibody can be swapped to recognize different tumor proteins, the NIR-PICT3 platform could be adapted to treat a wide range of cancers beyond head and neck tumors. Researchers plan to engineer even smaller nanoparticles for clearer imaging and investigate the long-term biological effects of iron in the body before advancing to human clinical trials. Extending the therapy to deep-seated tumors will also require specialized light-delivery devices, as NIR light penetrates only a few centimeters into the body.
Why It Matters: Tumor heterogeneity remains a major barrier to targeted cancer therapies, as cells lacking the target antigen frequently survive treatment and drive recurrence. By uniting real-time MRI drug tracking with a photothermal bystander effect that eradicates untargeted neighboring cells, NIR-PICT3 addresses two critical clinical limitations of existing light-based treatments. This strategy advances organ-preserving oncology, which is particularly vital for head and neck cancer patients who risk losing the ability to chew, swallow, or speak following invasive surgery.
![]() |
| The original therapy destroys only cancer cells that carry the target protein (purple). Cells without it (blue) survive, and the tumor grows back. Bottom: In the new treatment, heat from the iron particles also kills the nearby blue cells, so the entire tumor can be destroyed. Image Credit: Matsuoka et al., Journal of Nanobiotechnology (2026) (CC BY-NC-ND 4.0) |
Residual cancer cells can evade even targeted therapies and drive tumor recurrence. In preclinical mouse and cell models, researchers at Nagoya University in Japan developed a modified light-based therapy designed to eliminate these otherwise refractory cells. The team adapted an existing near-infrared light treatment by conjugating approximately 20 nm iron oxide nanoparticles to a tumor-targeting antibody. In mice, the modified therapy produced greater tumor regression than the standard formulation and destroyed adjacent antigen-negative cancer cells that the original treatment does not bind. By generating localized heat that kills neighboring untargeted cells—a mechanism the authors term the “photothermal bystander effect”—the approach demonstrates a preclinical strategy for eliminating heterogeneous cancer cell populations that would otherwise survive. Repeated cycles of near-infrared irradiation also amplified the treatment’s effect by increasing tumor vascular permeability and enhancing subsequent nanoparticle accumulation. The findings were published in the Journal of Nanobiotechnology.
Light-Based Cancer Treatment and Its Limits
The original treatment, called near-infrared photoimmunotherapy (NIR-PIT), uses an antibody that targets a protein called epidermal growth factor receptor (EGFR) on cancer cells. The antibody is conjugated to a near-infrared photosensitizer dye. When clinicians irradiate a tumor with near-infrared light, the conjugate triggers rapid necrotic cell death in targeted cancer cells within minutes while largely sparing surrounding healthy tissue.
Preserving surrounding structures is particularly critical in head and neck cancers, where surgical resection can severely impair chewing, swallowing, or speech, whereas NIR-PIT aims to ablate localized tumors while minimizing functional damage. In 2020, Japan became the first country to grant the therapy conditional approval for unresectable locally advanced or locally recurrent head and neck cancer, and the treatment has advanced to late-stage clinical trials in the United States.
However, standard NIR-PIT faces two major technical limitations that this study sought to address. Tumors are biologically heterogeneous: some cancer cells express the target protein while others do not. Antigen-negative cells escape treatment and can drive tumor recurrence. Clinicians also lack a reliable noninvasive way to confirm drug delivery to deeper tumors because the photosensitizer dye’s fluorescence penetrates only superficial tissue layers and degrades through photobleaching during light exposure.
.png)
The drug, an antibody carrying a light-activated dye and a tiny iron particle, collects in the tumor. When near-infrared light shines on the tumor, cancer cells are destroyed in three ways: they burst, they are heated, and they suffer chemical damage. The first round of light opens up the tumor’s blood vessels, so more particles enter, and later rounds produce more heat. Over repeated rounds, the tumor shrinks and can disappear.
Image Credit: Matsuoka et al., Journal of Nanobiotechnology (2026)
(CC BY-NC-ND 4.0)
Cancer-Targeting Antibody, Photosensitizer Dye, and Iron Oxide
To address both limitations, a team led by Kazuhide Sato, senior author and lecturer at Nagoya University’s Graduate School of Medicine, conjugated iron oxide nanoparticles approximately 20 nm in diameter to the antibody-dye complex. The researchers named this platform near-infrared photoimmuno-chemodynamic thermal targeting therapy (NIR-PICT³), reflecting its combined photoimmunological, chemodynamic, and photothermal mechanisms.
Previous attempts to deliver antibody-conjugated nanoparticles to solid tumors were often limited by rapid clearance in the liver and spleen. “Before this study, nanoparticles and antibodies could not reach the tumor because they were captured in the liver or spleen,” Sato said. “The size is very critical.”
Following intravenous administration in tumor-bearing mice, the nanoparticles accumulated in tumors, producing dark, negative-contrast signals on magnetic resonance imaging (MRI) scans within hours. This bimodal imaging capability allowed the researchers to track intratumoral drug delivery noninvasively. According to Sato, the pronounced intratumoral accumulation achieved through systemic intravenous injection was an unexpected finding of the study.
The iron oxide nanoparticles also generate heat when exposed to near-infrared light. Because nanoparticle accumulation and light irradiation are concentrated at the tumor site, this localized heat spreads to adjacent cancer cells within the tumor microenvironment—affecting both EGFR-positive and EGFR-negative cells—though maintaining thermal confinement at tumor margins remains a key consideration for sparing healthy tissue. To test this mechanism, the team treated mice bearing heterogeneous tumors composed of both antigen-positive and antigen-negative cancer cells. The modified therapy reduced overall volume in these mixed tumors, including antigen-negative cells that standard NIR-PIT failed to eliminate. “We named this the photothermal bystander effect,” Sato said. In separate in vitro experiments on human cancer cells, the iron oxide nanoparticles also induced chemodynamic reactions that contributed to cellular damage.
The therapeutic effect also intensified across repeated irradiation cycles. The initial round of near-infrared light increased tumor vascular permeability, enabling additional nanoparticles to enter and accumulate inside the tumor prior to subsequent exposures, with each successive cycle generating greater thermal output. In mice with homogeneous tumors uniformly expressing EGFR, treatment reduced tumor volume and prolonged survival compared with controls. Complete remission occurred in 4 of 10 treated mice (n = 10) in the homogeneous tumor group and in 3 of 6 treated mice (n = 6) bearing mixed tumors containing both antigen-positive and antigen-negative cells—promising early findings, though derived from small preclinical cohorts. In short-term safety assessments, treated mice showed no significant weight loss, and blood tests revealed no signs of liver damage. Evaluating chronic organ accumulation, splenic clearance, and immune-mediated toxicity will require broader preclinical studies before human testing.
Adapting for Other Cancers and Next Steps
Sato, an oncologist by training, hopes eventually to evaluate the therapy in clinical trials. Although larger, unconjugated iron oxide nanoparticles have previously received clinical approval as MRI contrast agents, this smaller multicomponent conjugate exhibits distinct biodistribution and will still require dedicated preclinical toxicology and pharmacokinetic studies before testing in humans. In vitro tests on human cancer cells also indicated that the antibody component can be exchanged to target other tumor-associated proteins, suggesting potential adaptability to additional cancer types, though this versatility has not yet been demonstrated in vivo.
Current findings are limited to cell culture and mouse models, and substantial translational work remains. Because near-infrared light penetrates only about 1 to 2 cm into biological tissue, treating deep-seated tumors will require specialized interstitial or endoscopic light-delivery devices. The long-term biological fate and potential toxicity of retained iron in the body also require further investigation. Next, the research team plans to engineer even smaller nanoparticles to further optimize MRI contrast clarity and imaging performance.
Funding: This work was supported by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI; 21K07217, 25K03451, 25K22916), the Japan Science and Technology Agency (JST) Fusion Oriented Research for Disruptive Science and Technology (FOREST) Program (JPMJFR2017), the Japan Agency for Medical Research and Development (AMED) Seeds A (26ym0126807j0005, A-226), the Ministry of Education, Culture, Sports, Science and Technology (MEXT) Advanced Research Infrastructure for Materials and Nanotechnology in Japan (ARIM Japan), JST Tongali, and research scholarships or grants from the Toyota Physical and Chemical Research Institute, the Sumitomo Electric Group CSR Foundation, the Takeda Science Foundation, the SGH Foundation, the Japanese Society for Thermal Medicine, the Chemo-Sero-Therapeutic Research Institute, the Suzuki-Kenzo Scholarship, the Terumo Science Foundation, the Tatematsu Foundation, and the Iketani Science Foundation.
Published in journal: Journal of Nanobiotechnology
Authors: Kohei Matsuoka, Mizuki Yamada, Ryu Okada, Mibuko Shimada, Mikina Yoshida, Rika Fukushima, Kanna Umeda, Ayano Ohashi, Chiemi Oka, Ayako Kato, Misae Shimizu, Chiaki Koike, Akira Ito, Mitsuo Sato, and Kazuhide Sato
Source/Credit: Nagoya University
Edited by: Scientific Frontline
Reference Number: med112026_01
.png)